maraviroc
Selected indexed studies
- Maraviroc. (Drugs Today (Barc), 2007) [PMID:18174962]
- Maraviroc. (Drugs, 2007) [PMID:17927288]
- Multiomics and cellular senescence profiling of aging human skeletal muscle uncovers Maraviroc as a senotherapeutic approach for sarcopenia. (Nat Commun, 2025) [PMID:40617829]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Maraviroc. (2007) pubmed
- Maraviroc. (2007) pubmed
- Multiomics and cellular senescence profiling of aging human skeletal muscle uncovers Maraviroc as a senotherapeutic approach for sarcopenia. (2025) pubmed
- Maraviroc: a new CCR5 antagonist. (2009) pubmed
- Off-label use of maraviroc in clinical practice. (2016) pubmed
- Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. (2008) pubmed
- Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. (2009) pubmed
- Maraviroc: pharmacokinetics and drug interactions. (2009) pubmed
- Maraviroc Prevents Optic Nerve Injury-Induced Retinal Ganglion Cell Apoptosis by Modulating the CCL5/CCR5/CTSS Axis. (2025) pubmed
- CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model. (2024) pubmed